Dysfunctional BMPR2 signaling drives an abnormal endothelial requirement for glutamine in pulmonary arterial hypertension

Robert A. Egnatchik1,2, Evan L. Brittain3, Amy T. Shah4, Wassim H. Fares5, H. James Ford6, Ken Monahan3, Christie J. Kang7, Emily G. Kocurek7, Shijun Zhu7, Thong Luong7, Thuy T. Nguyen8, Erik Hysinger9, Eric D. Austin10, Melissa C. Skala4,11,*, Jamey D. Young2,12, L. Jackson Roberts II8, Anna R. Hemnes7, James West4,7 and Joshua P. Fessel7,8,11

1Children’s Medical Center Research Institute, University of Texas Southwestern, Dallas, TX, USA; 2Department of Chemical and Biomolecular Engineering, Vanderbilt University, Nashville, TN, USA; 3Division of Cardiovascular Medicine and the Vanderbilt Translational and Clinical Cardiovascular Center, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA; 4Department of Biomedical Engineering, Vanderbilt University, Nashville, TN, USA; 5Section of Pulmonary, Critical Care & Sleep Medicine, Department of Medicine, Yale University, New Haven, CT, USA; 6Division of Pulmonary Diseases and Critical Care Medicine, Department of Medicine, University of North Carolina Chapel Hill, Chapel Hill, NC, USA; 7Division of Allergy, Pulmonary and Critical Care Medicine, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA; 8Division of Pharmacology, Vanderbilt University, Nashville, TN, USA; 9Division of Pulmonary Medicine, Children’s Hospital of Philadelphia, Philadelphia, PA, USA; 10Division of Pulmonary Medicine, Department of Pediatrics, Vanderbilt University Medical Center, Nashville, TN, USA; 11Department of Cancer Biology, Vanderbilt University, Nashville, TN, USA; 12Department of Molecular Physiology and Biophysics, Vanderbilt University, Nashville, TN, USA; *Dr. Skala’s current affiliation is Morgridge Institute for Research and Department of Biomedical Engineering, University of Wisconsin, Madison.

Abstract

Pulmonary arterial hypertension (PAH) is increasingly recognized as a systemic disease driven by alteration in the normal functioning of multiple metabolic pathways affecting all of the major carbon substrates, including amino acids. We found that human pulmonary hypertension patients (WHO Group I, PAH) exhibit systemic and pulmonary-specific alterations in glutamine metabolism, with the diseased pulmonary vasculature taking up significantly more glutamine than that of controls. Using cell culture models and transgenic mice expressing PAH-causing BMPR2 mutations, we found that the pulmonary endothelium in PAH shunts significantly more glutamine carbon into the tricarboxylic acid (TCA) cycle than wild-type endothelium. Increased glutamine metabolism through the TCA cycle is required by the endothelium in PAH to survive, to sustain normal energetics, and to manifest the hyperproliferative phenotype characteristic of disease. The strict requirement for glutamine is driven by loss of sirtuin-3 (SIRT3) activity through covalent modification by reactive products of lipid peroxidation. Using 2-hydroxybenzylamine, a scavenger of reactive lipid peroxidation products, we were able to preserve SIRT3 function, to normalize glutamine metabolism, and to prevent the development of PAH in BMPR2 mutant mice. In PAH, targeting glutamine metabolism and the mechanisms that underlie glutamine-driven metabolic reprogramming represent a viable novel avenue for the development of potentially disease-modifying therapeutics that could be rapidly translated to human studies.

Keywords

glutaminolysis, metabolic reprogramming, mitochondria, bone morphogenic protein receptor type 2 (BMPR2), tricarboxylic acid (TCA) cycle

Date received: 6 September 2016; accepted: 16 November 2016

Pulmonary Circulation 2017; 7(1) 186–199
DOI: 10.1177/2045893216685035

Alterations in the normal metabolic strategies utilized by various cell types are increasingly recognized as part of a central pathogenic mechanism in pulmonary arterial hypertension (PAH). Any given cell type—endothelium, smooth
muscle, myocardium, skeletal muscle, etc.—exhibits a “metabolic program” under healthy, homeostatic conditions that is the sum total of the use and fate of all of the available carbon sources (primarily carbohydrates, fats, and amino acids). The details of a cell’s metabolic program are often particular for that cell type. For example, under normal conditions, cardiac myocytes primarily oxidize fatty acids as an energy source, whereas endothelial cells preferentially use glucose through oxidative and non-oxidative pathways. Any perturbation that places demands upon a cell to increase energy production, to increase macromolecule synthesis, or to resist pro-death stimuli will place a strain on the cell’s carbon resources and necessarily change the cell’s metabolic program. Conversely, anything that restricts a cell’s ability to use one or more carbon substrates can induce a metabolic reprogramming that will often change one or more fundamental properties of the cell, such as differentiation state, proliferative rate, or sensitivity to apoptosis. Thus, a cell’s metabolic program is inextricably linked to the role that cell plays in health and disease.

In PAH, it is well recognized that multiple cell types involved in disease pathogenesis exhibit a metabolic reprogramming characterized by increased shunting of glucose-derived carbon into non-oxidative, lactate-producing pathways in spite of the presence of ample oxygen supply to permit oxidative glucose metabolism. This is colloquially referred to as the “Warburg effect,” first described by Otto Warburg as a feature of cancer cells. However, the network of metabolic pathways within a cell is highly interconnected and it is rare for one pathway to be altered in isolation. Indeed, it is increasingly recognized that fatty acid metabolism is also markedly altered in PAH and that the reciprocal relationship between glucose and fatty acid oxidation (the so-called “Randle cycle”) is abnormal in PAH and likely contributes to pathogenesis in both the heart and in the pulmonary vasculature. The third major cellular carbon source—amino acids generally, and glutamine specifically—remains relatively understudied in PAH. Though amino acids represent the third major carbon source used by most cells, amino acid trafficking has mainly been studied in PAH in the context of nitric oxide synthesis. Recent discoveries in cancer biology have placed amino acids generally, and glutamine specifically, in central roles for biosynthesis, cellular energetics, and redox homeostasis. In the present study, we sought to examine glutamine metabolism in PAH in the specific context of dysfunctional signaling through bone morphogenetic protein receptor type 2 (BMPR2). We hypothesized that the pulmonary endothelium in PAH would exhibit an abnormal increase in glutamine metabolism as a primary carbon source, in a manner similar to what has been observed in cancer.

**Materials and methods**

**Reagents**

$^{13}$C$_5$-L-glutamine was purchased from Sigma-Aldrich (St. Louis, MO, USA). Chetomin was purchased from Cayman Chemical (Ann Arbor, MI, USA). 2-hydroxybenzylamine (2HOB) was synthesized at Vanderbilt as previously described. Antibodies were purchased as follows: HIF1α and glucose synthetase, Novus Biologicals (Littleton, CO, USA); Sirt3 and α-tubulin, Cell Signaling Technology (Danvers, MA, USA); acetyl-lysine, EMD Millipore (Billerica, MA, USA); and Cox4 and histone H3, Abcam (Cambridge, MA, USA). Recombinant human SIRT3 was purchased from R&D Systems (Minneapolis, MN, USA). Sirt-Glo assay kit was purchased from Promega (Madison, WI, USA) and used according to the manufacturer’s instructions.

**Cell culture**

We used previously characterized wild-type (WT) and BMPR2 mutant (BMPR2$^{R899X}$) pulmonary microvascular endothelial cells (PMVECs) isolated from conditionally immortalized murine lines generated on the ImmortoMouse background, and WT and BMPR2 mutant PMVECs from a parent immortalized human line stably expressing either a WT or BMPR2 mutant construct transfected into the parent line and maintained under selection with G418S. For murine lines, cells were reverted to a primary endothelial phenotype by removal of murine interferon-gamma and transition to 37°C (from 33°C, which maintains conditional immortal phenotype through expression of SV40 large T), and doxycycline (300 ng/mL) was added to the media to induce expression of the transgene (the construct being Rosa26-rtTA x TetO7-Bmpr2R899X, the same as that used in Animal Studies), both for at least 72 h prior to experiments. Human lines stably express WT or mutant BMPR2, and selection with G418S was discontinued for 24h prior to experiments.

**Metabolic fluxes and stable isotope labeling**

Glucose and lactate levels were measured using the YSI 2300 Stat Glucose and Lactate Analyzer (Yellow Springs, OH, USA). High performance liquid chromatography (HPLC) was used to quantify amino acid concentrations with norvaline as an internal standard. Amino acid samples were then injected onto a Zorbax Eclipse Plus C18 column (Agilent) using a two-phase chromatography method as previously described. For isotope tracer studies, WT and BMPR2 mutant PMVECs were cultured in media containing 2 mM [U-$^{13}$C$_5$]-glutamine in place of unlabeled glutamine for 24 h. Analytes were extracted into ice-cold methanol and separated in 1:1 chloroform:H$_2$O. The aqueous phase containing the amino and organic acids was then dried under air at room temperature. The samples were derivatized using MBTSTFA +1% TBDMS (Pierce). A total of 2 µL of each derivatized sample was then injected onto 30 m DB-35ms capillary column in an Agilent 6890N/5975B GC-MS. Flux rates were calculated using the ETA software package.
**Cell proliferation assays**

Cells were seeded and grown under specified media conditions as outlined in the “Results” section. Cells were counted for total and live cells using Trypan blue exclusion, and automated counts were done using a Countess cell counter (Life Technologies, Grand Island, NY, USA).

**Two-photon autofluorescence measurement of optical redox ratio**

Two-photon images were acquired and analyzed as described previously. Briefly, cells were plated at a consistent density on glass-bottomed dishes and imaged 48 h later. A two-photon microscope (Bruker) and 40× oil-immersion objective (1.3 NA) were used to acquire NADH and FAD autofluorescence images for the same fields of view. Images were imported into MATLAB (Mathworks) and the NADH intensity was divided by the FAD intensity for each pixel to calculate a redox ratio image. The redox ratio was averaged across each image.

**Mitochondrial functional studies**

To assess mitochondrial respiration in cultured PMVECs, cells were seeded in growth media in a 96-well plate from Seahorse Biosciences (Billerica, MA, USA) at a seeding density of 50,000 live cells per well. The following day, cells were washed and placed in Seahorse Assay Media supplemented with specific substrates (1 gm/L glucose, 2 mM L-glutamine). After equilibration, oxygen consumption rates were measured on a Seahorse XFe96 analyzer using the Mito Stress Test protocol.

For mitochondrial protein measurements, mitochondria were isolated from fresh murine liver tissue as previously described.

**Animal studies**

All animal studies were approved by the Vanderbilt IACUC. Male and female FVB/N mice were aged 10–16 weeks. BMPR2<sup>Rs599X</sup> mice were generated and maintained as previously described. For 2HOB studies, 1 gm/L was administered in the drinking water, with water bottles protected from light and water changes every 2–3 days.

Echocardiography was performed on anesthetized mice (isoflurane anesthesia) to determine cardiac output. Right ventricular systolic pressure (RVSP) was invasively measured as described, using bromoethanol as the anesthetic.

**Human studies**

All human studies were approved by the Institutional Review Boards of Vanderbilt University, the University of North Carolina at Chapel Hill, and Yale University. Informed consent was obtained from each patient. For measurements of circulating glutamine levels, blood samples were obtained by peripheral venipuncture, centrifuged to separate plasma, and stored at ~80°C until analysis. Amino acid profiles were quantified in Vanderbilt’s clinical chemistry laboratory using a standard CLIA-approved method. For transpulmonary measurements, samples were obtained at the time of clinically indicated diagnostic right heart catheterization as previously described. Patients were classified as having pulmonary hypertension (PH) based upon the results of invasive hemodynamic testing, with differences between WHO groups determined by clinical history.

**Statistical analyses**

All statistics were performed using GraphPad Prism 6.0 or Microsoft Excel unless otherwise specified. For animal experiments, sample sizes were chosen based upon previous experiments with approximately 80% of transgenic animals showing RVSP > 30 mmHg. Animals were randomly assigned to treatment groups by cage. For all measurements, investigators were blind to treatments and genotype until data analysis. Data were analyzed using two-tailed t-test or two-way ANOVA with Tukey’s post-test, as indicated. Significance was set at α < 0.05 after correction for multiple comparisons.

**Results**

**Glutamine metabolism is abnormal in human PAH patients**

To test the hypothesis that PAH involves alteration of glutamine metabolism, we quantified fasting serum glutamine levels in heritable PAH patients with known BMPR2 mutations, in unaffected mutation carriers (individuals with known BMPR2 mutations but no evidence of PAH), and in married-in controls from the same households as patients and carriers. We found that circulating glutamine levels were significantly elevated in both heritable PAH patients (451 ± 68 umol/L) and in BMPR2 mutation carriers (450 ± 50 umol/L) compared to controls (399 ± 82 umol/L, P < 0.05, Fig. 1a). This was somewhat unexpected, as previous work has suggested increased cardiac glutamine uptake is a feature of the aberrant metabolic program in PAH. To better quantify glutamine metabolism within the pulmonary vasculature, we measured transpulmonary glutamine gradients in WHO Group I PAH patients, WHO Group III PH patients, and individuals with normal pulmonary hemodynamics. Samples were collected from the main pulmonary artery (PA) and from the pulmonary capillary wedge (PCW) position at the time of diagnostic right heart catheterization. Glutamine concentrations were quantified in each sample and the difference between the PCW and the PA samples for each individual was the gradient measurement (negative values indicate net uptake, positive values indicate net release). WHO Group I PAH
patients showed substantial glutamine uptake by the pulmonary vasculature compared to WHO Group III patients and to controls (Fig. 1b). Taken together, these data indicated that PAH patients with abnormal BMPR2 function have marked changes in whole body and in pulmonary vascular glutamine metabolism.

**BMPR2 mutant endothelium exhibits abnormal avidity for glutamine carbon**

We next sought to determine whether increased glutamine uptake by pulmonary endothelial cells with dysfunctional BMPR2 is an intrinsic property of those cells or merely due to the increased availability of glutamine. To assess this, we grew WT and BMPR2 mutant PMVECs in culture and provided glutamine in significant excess (2 mM) of physiologic levels in the culture media. Under conditions of glutamine excess, BMPR2 mutant PMVEC took up glutamine at twice the rate of WT cells (Fig. 2a), suggesting that increased glutamine uptake is intrinsic to PMVEC with dysfunctional BMPR2 signaling.

Glutamine can be used as a source of carbon input to the tricarboxylic acid (TCA) cycle, but it is also an important source of nitrogen in the cell, supplying nitrogen-requiring processes such as nucleotide synthesis. We hypothesized that glutamine was being used as a carbon source and that it was being preferentially shunted to the TCA cycle in BMPR2 mutant PMVEC compared to WT. To test this hypothesis, WT and BMPR2 mutant PMVEC were cultured for 24 h in the presence of 2 mM [U-13C5]-L-glutamine, a stable isotope of glutamine in which all five carbon atoms are carbon-13, which is easily detectable by mass spectrometry (see schematic Fig. 2b). The other major cellular carbon sources (glucose, fatty acids) were left unlabeled and the serum used had been dialyzed to remove free amino acids. Compared to WT, BMPR2 mutant PMVECs showed excess incorporation of glutamine-derived carbon in multiple intermediates of the TCA cycle (Fig. 2c). Furthermore, when specific TCA intermediates (e.g. malate) were broken down by tandem mass spectrometry to determine how many glutamine-derived carbon atoms had been incorporated (0, 1, 2, 3, or 4 for malate), we found that the majority of malate present (40%) contained four atoms of 13C, indicating that the majority of the carbon in the TCA cycle was coming from glutamine, as this was the sole source of 13C available (Fig. 2d). By contrast, in WT PMVECs, the majority of the malate present (>55%) contained no atoms of 13C, indicating that in WT cells, the majority of the carbon in the TCA cycle was not coming from glutamine but rather from the unlabeled glucose and fatty acids present.

**Glutamine is a required carbon source for BMPR2 mutant PMVECs**

We next wanted to determine whether BMPR2 mutant PMVECs have an absolute requirement for glutamine or whether this represented an “arrangement of convenience” as a result of the presence of excess glutamine. We cultured WT and BMPR2 mutant PMVECs in two concentrations of glutamine, 500 μM (mimicking serum concentrations in BMPR2 mutant patients) and 200 μM (representing the lowest levels that would be considered normal in humans). At 500 μM glutamine, BMPR2 mutant PMVECs show a net proliferation that exceeds the rate of WT PMVECs at all timepoints out to 72 h (Fig. 3a). At 200 μM glutamine, the net proliferative rate of WT PMVECs is essentially unchanged, but the BMPR2 mutant PMVECs are completely intolerant of glutamine-limited conditions and have all died by 72 h (Fig. 3b).

To better understand the details of glutamine utilization and the effects of glutamine limitation in BMPR2 mutant PMVECs, we quantified total intracellular redox status of WT and BMPR2 mutant PMVECs using two-photon autofluorescence of endogenous NADH and FAD, the major
electron carriers controlled by TCA cycle activity. Fluorescence from both species allows calculation of the optical redox ratio, with a higher ratio indicating more TCA cycle activity, a more reduced intracellular redox environment, and increased overall metabolic activity. Conversely, a reduction in the optical redox ratio indicates an overall decrease in metabolic activity, particularly via the TCA cycle.28–30 Two-photon autofluorescence has very high time resolution, allowing for rapid changes in the metabolic and redox status of the cell to be detected and quantified. We quantified the optical redox ratio in WT and BMPR2 mutant PMVECs under basal conditions and with acute withdrawal of glutamine and glucose. At baseline, BMPR2 mutant PMVECs have a lower optical redox ratio than WT cells (Fig. 4a), indicating a relatively impaired ability to maintain the intracellular redox environment and relatively impaired overall metabolic activity. With acute limitation of TCA cycle substrates, WT PMVECs are able to rapidly adapt their metabolic behavior to maintain the optical redox ratio (Fig. 4a), whereas BMPR2 mutant PMVECs show a significant further reduction in the optical redox ratio (Fig. 4a), suggesting a significant loss of acute metabolic flexibility.

We next examined the consequences of TCA cycle glutamine dependence on mitochondrial function in BMPR2 mutant PMVECs. Cultured WT and BMPR2 mutant PMVECs were given either glucose or glutamine as the sole energy substrate available. Mitochondrial oxygen consumption was quantified using the Seahorse XFe96 analyzer and specific components of cellular respiration (ATP-linked respiration, proton leak, and coupling efficiency) were calculated from the oxygen consumption profiles.
WT PMVECs show equivalent ATP-linked respiration with glucose or glutamine as the sole carbon source, but BMPR2 mutant PMVECs show enhanced ATP-linked respiration with glutamine as their carbon source compared to glucose (Fig. 4b). When using glutamine, WT PMVECs exhibit increased proton leak in the mitochondria compared to when using glucose, but BMPR2 mutant cells maintain low levels of proton leak with either glutamine or glucose (Fig. 4c), suggesting that the overall efficiency for use of glutamine as a fuel to support ATP synthesis is much greater in BMPR2 mutant PMVECs compared to WT. Consistent with this, when comparing ATP-linked respiration to basal respiration, WT endothelial cells exhibited a lower coupling efficiency when using glutamine as fuel, whereas BMPR2 mutant PMVECs maintain a high coupling efficiency (Fig. 4d). Taken together, these data indicated that glutamine is the preferred substrate for energy production in BMPR2 mutant PMVECs.

Oxidative stress drives HIF activation and SIRT3 impairment in BMPR2 mutants

We next wished to determine the molecular events downstream from BMPR2 mutation that contribute to glutamine reliance. Multiple signaling pathways have been shown to regulate increased glutamine utilization in a variety of disease contexts.15,31–35 Of the possible candidate pathways, the pathway with the greatest relevance to PAH that also potently regulates glutamine metabolism is hypoxia-inducible factor 1-alpha (HIF1α). HIF1α has been shown to be stabilized under normoxic conditions in experimental and human PAH, and activation of HIF1α can induce glutamine reliance.36–39 We found that BMPR2 mutant PMVECs grown in culture exhibited significant normoxic stabilization of HIF1α at the protein level compared to WT (Fig. 5a and 5b), and that this was demonstrable for two different PAH-associated BMPR2 mutation types. We then treated WT and BMPR2 mutant PMVECs with chetomin, a pharmacologic inhibitor of HIF, and assessed glucose and glutamine uptake by quantifying the extracellular flux ratio of glutamine to glucose. Treatment of WT cells had no effect on the glutamine to glucose flux ratio (Fig. 5c). However, treating BMPR2 mutant PMVECs with the HIF inhibitor significantly reduced the glutamine to glucose flux ratio (Fig. 5c), suggesting that HIF1α activity helps to drive the glutamine requirement in BMPR2 mutant endothelium.

Though HIF1α activation contributes to glutamine uptake and utilization in BMPR2 mutant cells, we suspected that there were additional alterations in signaling pathways known to control metabolism. Activation of HIF1α by itself has been shown to drive glutamine metabolism, but the glutamine is disproportionately used for biosynthesis.39–41 Given the finding that glutamine in BMPR2 mutant PMVECs is being used for energy production and not obviously for disproportionate biosynthesis, we hypothesized that a metabolic control pathway directly involved in both glutamine regulation and energy production was likely altered. Sirtuin-3 (SIRT3), a lysine deacetylase involved in mitochondrial energy production and redox homeostasis, emerged as a strong candidate. Loss of SIRT3 has been shown to lie upstream of HIF1 activation and has been associated with PH.15,42–44

Because sirtuin expression and activity is tightly regulated by substrate availability, nutrient intake, physical activity, and interacting signaling pathways operating between organ systems, the role of SIRT3 in BMPR2-mediated PAH is best studied in a murine model system. To investigate the role of
SIRT3 inactivation in BMPR2-mediated PAH, we isolated mitochondria from WT and BMPR2 mutant (BMPR2R899X) mice fed a Western diet (60% calories from fat) for 8 weeks. Quality of the mitochondria-enriched fraction was confirmed (Supplemental Figure 2) by demonstrating the presence of COX4 and the absence of histone H3 (nuclear protein) and α-tubulin (cytosolic protein), and the mitochondrial proteome was assessed for acetylation of lysine residues, with SIRT3 inactivation leading to lysine hyperacetylation. Compared to WT, BMPR2R899X mitochondria had equivalent protein levels of SIRT3 but exhibited significant lysine hyperacetylation of multiple mitochondrial proteins (Fig. 6a, lanes 1–2 for WT and 5–6 for mutants, quantified in Fig. 6d), consistent with loss of SIRT3 activity in BMPR2R899X mice.

Hyperacetylation of the mitochondrial proteome with no change in SIRT3 protein content is consistent with loss of SIRT3 enzymatic activity. We have previously shown that the mitochondrial membranes specifically in BMPR2R899X mice exhibit extensive lipid peroxidation as a function of expression of the mutant BMPR2 isoform, and that the lipid peroxidation is characterized by excess production of covalent adducts between proteins and isoketals, a subset of highly reactive lipid peroxidation products, specifically in the lung around the microvessels. We and others have also shown that lipid peroxidation products are increased in humans with PAH. We thus hypothesized that SIRT3 was undergoing oxidative inactivation in the mitochondria of BMPR2R899X mice, and that treatment with the isoketal scavenger 2HOBA would restore normal SIRT3 activity (schematic in Fig. 6b). We demonstrated the biochemical plausibility of this hypothesis by incubating synthetically pure isoketal with recombinant human SIRT3 in vitro. Isoketal treatment inactivated SIRT3 in a concentration-dependent manner as measured by luminescence via the Sirt-Glo assay (Fig. 6c). We then directly tested the
hypothesis that scavenging isoketals would preserve SIRT3 function by treating WT and BMPR2 R899X mice with 1 g/L 2HOBA in their drinking water. Treatment with 2HOBA significantly reduced lysine acetylation in the mitochondrial proteome in BMPR2 R899X mice compared to WT without affecting total SIRT3 content in the mitochondria (Fig. 6a, lanes 3–4 for WT and 7–8 for mutants, quantified in Fig. 6d), consistent with preservation of SIRT3 catalytic activity.

2HOBA normalizes glutamine metabolism and prevents PAH in vivo

Having shown that impaired BMPR2 function is associated with loss of SIRT3 function, and that this can be prevented with 2HOBA treatment to scavenge damaging lipid peroxidation products, we next wished to assess the in vivo metabolic dysfunction downstream from BMPR2 mutation, the relationship to PAH, and the effect of 2HOBA treatment. We hypothesized that 2HOBA would prevent the development of PAH in BMPR2 R899X mice and would have a beneficial modulatory effect on glutamine metabolism in vivo. Expression of the BMPR2 R899X allele was sufficient to drive upregulation of glutamine synthetase in skeletal muscle (Supplemental Figure 3) and in liver mitochondria (Fig. 7a) compared to WT. Despite upregulation of glutamine synthetase, circulating glutamine concentrations were equivalent in vehicle-treated WT and BMPR2 R899X mice (Fig. 7b), suggesting that increased glutamine synthesis was being matched by increased consumption in the BMPR2 mutants. Following 2HOBA treatment, BMPR2 R899X mice had reduced glutamine synthetase in liver mitochondria (Fig. 7a) and significantly lower circulating glutamine compared to treated WT mice (Fig. 7b), suggesting a favorable effect on glutamine balance in the mutants. Consistent with the effects on SIRT3 and glutamine metabolism, 2HOBA treatment prevented the development of PH as measured by total pulmonary resistance in the BMPR2 R899X mice compared to vehicle-treated mice (Fig. 7c). Treatment with 2HOBA in the BMPR2 R899X mice modestly increased cardiac output (Supplemental Figure 4a) and decreased RVSP (Supplemental Figure 4b), the combined effect of which was to significantly reduce total pulmonary resistance.

Discussion

In these studies, we have used human and murine cell culture models, transgenic mice, and samples from living PAH...
patients to demonstrate a markedly altered metabolic program for glutamine due to dysfunctional BMPR2 signaling (Fig. 8). Loss of normal BMPR2 function leads to oxidant injury in the mitochondria and formation of reactive products of lipid peroxidation termed isoketals. Isoketals inactivate SIRT3 which, together with increased oxidant stress, results in stabilization of HIF1α. Together, SIRT3 and HIF1α are two of the best established “master regulator” pathways for cellular metabolism generally and glutamine metabolism specifically. We show that this process can be interrupted in vivo by treating with an orally bioavailable scavenger of isoketals—2HOBA—and that interruption of the molecular cascade leading to glutamine addiction prevents the development of PAH.

Our findings add to the rapidly growing weight of evidence implicating altered cellular metabolism as a major contributor to the development and maintenance of PH. The first major metabolic perturbation described in PAH was a shift to lactate-producing glycolysis despite the presence of ample oxygen concentrations to permit complete glucose oxidation. This finding has now been replicated in virtually every setting of experimental and human PAH, and the molecular underpinnings continue to be clarified. However, as has also been true for cancer research, we and others are finding that the changes to the cellular metabolic landscape in PAH are not restricted to glycolysis, but rather appear to involve most of the major metabolic pathways. Given the interconnectedness of the
metabolome in healthy cells, this is perhaps not surprising. Indeed, we have previously shown that expression of mutant isoforms of BMPR2 in PMVECs is sufficient to reprogram multiple metabolic pathways.51 Our findings help bring together several other recently published reports concerning the altered metabolic program in PH. Piao et al. showed increased right ventricular (RV) glutaminolysis in monocrotaline-treated rats, and that a signature of increased glutaminolysis was also present in the RV from human PAH patients.14 Paulin et al. recently published that loss of SIRT3 activity through reduction at the protein level predisposed mice to the development of PAH, though the mechanism of downregulation was not entirely clear.44 Extending these findings, Lai et al. have very recently shown an important role for SIRT3 in PH and the associated systemic metabolic derangements seen in left heart failure with preserved ejection fraction.53 Diebold et al. reported metabolic remodeling in pulmonary endothelial cells with reduced BMPR2 expression, though manifestation of the PAH phenotype required exposure to hypoxia, implicating HIF but not SIRT3.50,54 Our findings fill in important gaps within and between these studies by providing a possible mechanism by which all of these published findings could be consistent with one another. In addition, we provide evidence in living PAH patients that dynamic metabolism is in fact reprogrammed in a manner similar to what has been observed in model systems and postmortem tissue. We have also shown that targeting at least one of the mechanisms underlying metabolic reprogramming in PAH has beneficial effects in vivo, and we have done so with a compound that can be used in humans. 2HOBA has a very favorable long-term safety profile, with over 12 months of continuous dosing in mice producing no significant toxicity. 2HOBA is a naturally occurring product, allowing expedited proof-of-principle studies in humans, with subsequent studies focusing on related compounds with improved pharmacokinetics. Importantly, 2HOBA’s mechanism of action has been demonstrated in other disease models and across species.19,55

Fig. 7 2HOBA lowers circulating glutamine and prevents the development of PAH in BMPR2R899X mice. (a) Glutamine synthetase in the liver mitochondrial fraction is elevated in BMPR2R899X mice (lanes 5–6) compared to WT (lanes 1–2). 2HOBA treatment reduced glutamine synthetase in the BMPR2R899X mice (lanes 7–8) but not substantially in WT (lanes 3–4). Western images are separate serial exposures of the same blot following stripping and reprobing with antibodies to the indicated proteins. (b) Treatment with 2HOBA significantly reduces plasma glutamine availability in BMPR2R899X mice compared to 2HOBA-treated WT mice. n = 6–29, *P < 0.05. (c) 2HOBA treatment reduced total pulmonary resistance in BMPR2R899X mice to a level statistically indistinguishable from WT. n = 5–14, *P < 0.02 by ANOVA with Tukey post-hoc analysis.
data indicate that complex carbon cycling through the pyruvate pool is occurring, as shown by the presence of the M3 isotopemer in the BMPR2 mutant PMVECs (Fig. 2d) and the presence of excess label incorporation in the alanine pool but not in the lactate pool (Supplemental Figure 5). This may be related to a degree of carbon flux through the pyruvate carboxylate pathway, as has been found in another recent study examining upregulation of vascular glutaminolysis in PAH.56 A deeper understanding of the utilization and trafficking of glutamine as a carbon source in PAH will be a goal of our ongoing studies, not only to address these questions, but also to address issues such as how changes in TCA intermediates such as succinate or 2-oxoglutarate (neither of which were quantified in the present study, but which very likely are impacted by changes in glutamine metabolism) may impact directly on HIF activation.37,58 Besides engaging in complex biochemistry as a carbon source, glutamine can also serve as an important nitrogen source, contributing to biosynthetic pathways for nucleic acids and amino acids as well as participation in the urea cycle and nitrogen cycling pathways. Our studies were not structured to capture this aspect of glutamine metabolism and this will likely be a fruitful avenue of inquiry in future studies. Our work deliberately did not address the use and fate of fat-derived carbon in BMPR2 mutant endothelium. Fatty acid carbon trafficking is much more important in normal endothelial biology than was previously realized.59 While we have previously addressed fatty acid metabolism in BMPR2 mutant tissues, and we have previously shown evidence for downregulation of key fat metabolism genes in BMPR2 mutant pulmonary endothelial cells, the detailed complexities of utilization of multiple carbon sources were beyond the scope of this report.9,12,13,51

In summary, we have shown that metabolic reprogramming in the pulmonary endothelium driving BMPR2-mediated PAH involves glutamine addiction as an
important molecular feature. Glutamine becomes an indispensible, preferred carbon source in the BMPR2 mutant pulmonary endothelium, permitting hyperproliferation characteristic of PAH. Glutamine addiction appears to be driven downstream from BMPR2 by decreases in SIRT3 activity and increased HIF1α signaling. Interruption of this pathway in BMPR2 mutant mice with a molecularly targeted therapy that is directly translatable to humans in large part ameliorates disease. The finding that glutamine avidity is present in humans with WHO Group I PAH suggests that 2HOBA and other therapies targeting metabolic reprogramming have a high likelihood of benefit in PAH and delays to trials of these interventions in PAH patients should be minimized.

Acknowledgements

The Seahorse Biosciences Extracellular Flux Analyzer used in the present study is housed and managed within the Vanderbilt High-Throughput Screening Core Facility, an institutionally supported core, and was funded by NIH Shared Instrumentation Grant S10 OD018015.

Conflict of interest

The author(s) declare that there is no conflict of interest.

Funding

These studies were funded by NIH grants K08 HL121174, K23 HL098743, R01 HL095797, R01 CA185747, P01 HL108800, T32 HL007106-34, T32 HL-007891; by American Heart Association Fellow to Faculty Grant #13FTF1607002; by a National Science Foundation (NSF) CAREER Award CBET-0955251 (JDY) and the NSF Graduate Research Fellowship Program (RAE, ATS); by the ENTELLIGENCE Young Investigators Program sponsored by Actelion Pharmaceuticals; by the Gilead Sciences Research Scholars Program in Pulmonary Arterial Hypertension; and by a Parker B. Francis Foundation fellowship. The project was also supported by CTSA award no. UL1TR000445 from the National Center for Advancing Translational Sciences.

Supplemental Material

Supplementary material for this paper can be found at http://journals.sagepub.com/doi/suppl/10.1177/2045893216685035

References

1. Sutendra G and Michelakis ED. The metabolic basis of pulmonary arterial hypertension. *Cell Metab* 2014; 19: 558–573.
2. Ryan JJ and Archer SL. Emerging concepts in the molecular basis of pulmonary arterial hypertension: part I: metabolic plasticity and mitochondrial dynamics in the pulmonary circulation and right ventricle in pulmonary arterial hypertension. *Circulation* 2015; 131: 1691–1702.
3. Taegtmeyer H, Young ME, Lopaschuk GD, et al. Assessing cardiac metabolism: a scientific statement from the American Heart Association. *Circ Res* 2016; 118: 1659–1701.
4. Eelen G, de Zeeuw P, Simons M, et al. Endothelial cell metabolism in normal and diseased vasculature. *Circ Res* 2015; 116: 1231–1244.
5. Gomez-Arroyo J, Mizuno S, Szczepanek K, et al. Metabolic gene remodeling and mitochondrial dysfunction in failing right ventricular hypertrophy secondary to pulmonary arterial hypertension. *Circ Heart Fail* 2013; 6: 136–144.
6. Ryan J, Dasgupta A, Huston J, et al. Mitochondrial dynamics in pulmonary arterial hypertension. *J Mol Med* 2015; 93: 229–242.
7. Obre E and Rossignol R. Emerging concepts in bioenergetics and cancer research: metabolic flexibility, coupling, symbiosis, switch, oxidative tumors, metabolic remodeling, signaling and bioenergetic therapy. *Int J Biochem Cell Biol* 2015; 59: 167–181.
8. Chen X, Talati M, Fessel JP, et al. Estrogen metabolite 16alpha-hydroxyestrone exacerbates bone morphogenetic protein receptor type II-associated pulmonary arterial hypertension through microRNA-29-mediated modulation of cellular metabolism. *Circulation* 2016; 133: 82–97.
9. Hemnes AR, Brittain EL, Trammell AW, et al. Evidence for right ventricular lipotoxicity in heritable pulmonary arterial hypertension. *Am J Respir Crit Care Med* 2014; 189: 325–334.
10. West J, Niswender KD, Johnson JA, et al. A potential role for insulin resistance in experimental pulmonary hypertension. *Eur Respir J* 2013; 41: 861–871.
11. Dyck JR, Hopkins TA, Bonnet S, et al. Absence of malonyl coenzyme A dehydrogenase in mice increases cardiac glucose oxidation and protects the heart from ischemic injury. *Circulation* 2006; 114: 1721–1728.
12. Talati MH, Brittain EL, Fessel JP, et al. Mechanisms of lipid accumulation in the bone morphogenic protein receptor 2 mutant right ventricle. *Am J Respir Crit Care Med* 2016; 194: 719–728.
13. Brittain EL, Talati M, Fessel JP, et al. Fatty acid metabolic defects and right ventricular lipotoxicity in human pulmonary arterial hypertension. *Circulation* 2016; 133: 1936–1944.
14. Piao L, Fang YH, Parikh K, et al. Cardiac glutaminolysis: a maladaptive cancer metabolism pathway in the right ventricle in pulmonary hypertension. *J Mol Med* 2013; 91: 1185–1197.
15. Li C, Zhang G, Zhao L, et al. Metabolic reprogramming in cancer cells: glycolysis, glutaminolysis, and Bcl-2 proteins as novel therapeutic targets for cancer. *World J Surg Oncol* 2016; 14: 15.
16. Yang C, Ko B, Hensley CT, et al. Glutamine oxidation maintains the TCA cycle and cell survival during impaired mitochondrial pyruvate transport. *Mol Cell* 2014; 56: 414–424.
17. Jiang L, Shestov AA, Swain P, et al. Reductive carboxylation supports redox homeostasis during anchorage-independent growth. *Nature* 2016; 532: 255–258.
18. DeBerardinis RJ and Chandel NS. Fundamentals of cancer metabolism. *Sci Adv* 2016; 2: e1600200.
19. Kirabo A, Fontana V, de Faria AP, et al. DC isoketal switch, oxidative tumors, metabolic remodeling, signaling and cancer research: metabolic flexibility, coupling, symbiosis, switch, oxidative tumors, metabolic remodeling, signaling and bioenergetic therapy. *Cell Metab* 2014; 19: 558–573.
22. Murphy TA and Young JD. ETA: robust software for determination of cell survival rates from extracellular time courses. *Biotechnol Bioeng* 2013; 110: 1748–1758.

23. Shah AT, Demory Beckler M, Walsh AJ, et al. Optical metabolic imaging of treatment response in human head and neck squamous cell carcinoma. *PLoS One* 2014; 9: e90746.

24. Fessel JP, Flynn CR, Robinson LJ, et al. Hyperoxia synergizes with mutant bone morphogenetic protein receptor 2 to cause metabolic stress, oxidant injury, and pulmonary hypertension. *Am J Respir Cell Mol Biol* 2013; 49: 778–787.

25. Johnson JA, Hennes AR, Perrien DS, et al. Cytoskeletal defects in Bmpr2-associated pulmonary arterial hypertension. *Am J Physiol Lung Cell Mol Physiol* 2012; 302: L474–484.

26. Fares WH, Ford HJ, Ghio AJ, et al. Safety and feasibility of obtaining wedged pulmonary artery samples and differential distribution of biomarkers in pulmonary hypertension. *Pulm Circ* 2012; 2: 477–482.

27. Monahan K, Scott TA, Su YR, et al. Reproducibility of intra-cardiac and transpulmonary biomarkers in the evaluation of pulmonary hypertension. *Pulm Circ* 2013; 3: 345–349.

28. Skala MC, Riching KM, Gendron-Fitzpatrick A, et al. In vivo multiphoton microscopy of NADH and FAD redox states, fluorescence lifetimes, and cellular morphology in precancerous epithelia. *Proc Natl Acad Sci U S A* 2007; 104: 19494–19499.

29. Chance B, Schoener B, Oshino R, et al. Oxidation-reduction ratio studies of mitochondria in freeze-trapped samples. NADH and flavoprotein fluorescence signals. *J Biol Chem* 1979; 254: 4764–4771.

30. Barlow CH, Harden WR 3rd, Harken AH, et al. Fluorescence mapping of mitochondrial redox changes in heart and brain. *Crit Care Med* 1979; 7: 402–406.

31. Sanchez EL and Lagunoff M. Viral activation of cellular metabolism. *Virology* 2015; 479-480: 609-618.

32. Hough KP, Chisolm DA and Weinmann AS. Transcriptional regulation of T cell metabolism. *Mol Immunol* 2015; 68: 520–526.

33. Courtmey R, Ngo DC, Malik N, et al. Cancer metabolism and the Warburg effect: the role of HIF-1 and PI3K. *Mol Biol Rep* 2015; 42: 841–851.

34. Ryan JJ and Archer SL. The right ventricle in pulmonary arterial hypertension: disorders of metabolism, angiogenesis and adrenergic signaling in right ventricular failure. *Circ Res* 2014; 115: 176–188.

35. Chen JQ and Russo J. Dysregulation of glucose transport, glycolysis, TCA cycle and glutaminolysis by oncogenes and tumor suppressors in cancer cells. *Biochem Biophys Acta* 2012; 1826: 370–384.

36. Tudor RM, Archer SL, Dorfmuller P, et al. Relevant issues in the pathology and pathobiology of pulmonary hypertension. *J Am Coll Cardiol* 2013; 62: D4–12.

37. Pisarcik S, Maylor J, Lu W, et al. Activation of hypoxia-inducible factor-1 in pulmonary arterial smooth muscle cells by endothelin-1. *Am J Physiol Lung Cell Mol Physiol* 2013; 304: L549–561.

38. Fijalkowska I, Xu W, Comhair SA, et al. Hypoxia inducible factor1alpha regulates the metabolic shift of pulmonary hypertensive endothelial cells. *Am J Pathol* 2010; 176: 1130–1138.

39. Wise DR, Ward PS, Shay JE, et al. Hypoxia promotes isocitrate dehydrogenase-dependent carboxylation of alpha-ketoglutarate to citrate to support cell growth and viability. *Proc Natl Acad Sci U S A* 2011; 108: 19611–19616.

40. Wise DR, DeBerardinis RJ, Mancuso A, et al. Myc regulates a transcriptional program that stimulates mitochondrial glutaminolysis and leads to glutamine addiction. *Proc Natl Acad Sci U S A* 2008; 105: 18782–18787.

41. Hosios AM, Hecht VC, Danai LV, et al. Amino acids rather than glucose account for the majority of cell mass in proliferating mammalian cells. *Dev Cell* 2016; 36: 540–549.

42. Haigis MC, Deng CX, Finley LW, et al. SIRT3 is a mitochondrial tumor suppressor: a scientific tale that connects aberrant cellular ROS, the Warburg effect, and carcinogenesis. *Cancer Res* 2012; 72: 2468–2472.

43. Finley LW, Carracedo A, Lee J, et al. SIRT3 opposes programming of cancer cell metabolism through HIF1alpha destabilization. *Cancer Cell* 2011; 19: 416–428.

44. Paulin R, Dromparis P, Sutendra G, et al. Sirtuin 3 deficiency is associated with inhibited mitochondrial function and pulmonary arterial hypertension in rodents and humans. *Cell Metab* 2014; 20: 827–839.

45. Lane KL, Talati M, Austin E, et al. Oxidative injury is a common consequence of BMPR2 mutations. *Pulm Circ* 2011; 1: 72–83.

46. Zhang R, Sun ML, Fan YF, et al. Plasma 15-F2t-isoprostane in idiopathic pulmonary arterial hypertension. *Int J Cardiol* 2014; 175: 268–273.

47. Monneret D, Cracowski JL and Bonnemont-Rousselot D. Isoprostane as a promising prognostic biomarker in pulmonary arterial hypertension: preanalytical and analytical viewpoints. *Int J Cardiol* 2014; 177: 527–528.

48. Dromparis P and Michelakis ED. F2-isoprostanes: an emerging pulmonary arterial hypertension biomarker and potential link to the metabolic theory of pulmonary arterial hypertension? *Chest* 2012; 142: 816–820.

49. Cracowski JL, Degano B, Chabot F, et al. Independent association of urinary F2-isoprostanes with survival in pulmonary arterial hypertension. *Chest* 2012; 142: 869–876.

50. Diebold I, Hennigs JK, Miyagawa K, et al. BMPR2 preserves mitochondrial function and DNA during reoxygenation to promote endothelial cell survival and reverse pulmonary hypertension. *Cell Metab* 2015; 21: 596–608.

51. Fessel JP, Hamid R, Wittmann BM, et al. Metabolomic analysis of bone morphogenetic protein receptor type 2 mutations in human pulmonary endothelium reveals widespread metabolic reprogramming. *Pulm Circ* 2012; 2: 201–213.

52. Xu W, Koeck T, Lara AR, et al. Alterations of cellular bioenergetics in pulmonary artery endothelial cells. *Proc Natl Acad Sci U S A* 2007; 104: 1342–1347.

53. Lai YC, Tabima DM, Dube JJ, et al. SIRT3-AMP-activated protein kinase activation by nitrite and metformin improves hyperglycemia and normalizes pulmonary hypertension associated with heart failure with preserved ejection fraction. *Circulation* 2016; 133: 717–731.

54. Waypa GB, Osborne SW, Marks JD, et al. Sirtuin 3 deficiency does not augment hypoxia-induced pulmonary hypertension. *Am J Respir Cell Mol Biol* 2013; 49: 885–891.

55. Nguyen TT, Caiot SW, Zackert WE, et al. Scavengers of reactive gamma-ketoaldehydes extend Caeonorhabditis elegans lifespan and healthspan through protein-level...
interactions with SIR-2.1 and ETS-7. Aging (Albany NY) 2016; 8: 1759–1780.

56. Bertero T, Oldham WM, Cottrill KA, et al. Vascular stiffness mechanoactivates YAP/TAZ-dependent glutaminolysis to drive pulmonary hypertension. J Clin Invest 2016; 126: 3313–3335.

57. Boulahbel H, Duran RV and Gottlieb E. Prolyl hydroxylases as regulators of cell metabolism. Biochem Soc Trans 2009; 37: 291–294.

58. Selak MA, Armour SM, MacKenzie ED, et al. Succinate links TCA cycle dysfunction to oncogenesis by inhibiting HIF-alpha prolyl hydroxylase. Cancer Cell 2005; 7: 77–85.

59. Schoors S, Bruning U, Missiaen R, et al. Fatty acid carbon is essential for dNTP synthesis in endothelial cells. Nature 2015; 520: 192–197.